Kuur Therapeutics

Please note: The information displayed on this page might be outdated.
Kuur Therapeutics: Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies.

Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.
Healthcare / Basic Materials/Steel
Based in...
Europe, US - West South Central
Disease Space
2617 Bissonnet St
Suite 300
Houston, TX 77005
United States

Company Participants at Fall Private Company Showcase 2020

Kevin Boyle
Kuur Therapeutics, Chief Executive Officer
Kevin S. Boyle, Sr. is Chief Executive Officer of Kuur Therapeutics, a position he has held since January 2020. He joined Kuur in 2018 as the company’s Chief Financial Officer. Kevin has over 20 years of experience helping companies define and execute strategy and increase shareholder value. He has broad international experience with both public and private companies and has raised over $2.0 billion in capital over his career. Before joining Kuur Therapeutics, Kevin served as Chief Financial Officer of FloWorks International and had held previous senior finance roles at Sigma Cubed, RecoverCare and SPT. Kevin graduated from Carnegie Mellon University with a B.S. in Industrial Management, and earned his J.D. from the University of Pennsylvania. He is active in the Houston community, serving as
Kurt Gunter
Kuur Therapeutics, Chief Medical Officer
Kurt has devoted his career to the development of cell and gene therapies and brings significant experience to Kuur Therapeutics from his previous positions at Hospira, ViaCell, and Transkaryotic Therapies. As past President of the International Society for Cellular Therapy (ISCT), Kurt played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies. Prior to his biotech career, he worked at the United States Food and Drug Administration as a Medical Officer in the Center for Biologics and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research. He also served for 5 years on FDA’s Cellular, Tissue and Gene Therapies Advisory Committee. Kurt earned his MD from the University of Kansas and also has a BS in biological sciences, with distinction, from Stanford University. His postdoctoral training included Johns Hopkins and the US National Institutes of Health.